Paradigm Biocapital Advisors LP
NEW YORK, NY · CIK 1855655 · 13F filing filed 2026-02-17
SEC-registered investment adviser since 2021 · limited partnership
- Assets managed$4.5bn
- Staff11 · 6 in investment roles
- Main clients (by assets)Private funds 90%
- Private funds2 (2 hedge) · $4.1bn gross assets
- Form ADV · 2026-08-27SEC adviser record
- Legal entityPARADIGM BIOCAPITAL ADVISORS LP (US)
- Kindhedge funds, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 2
$3.7bn
reported value
+10.5% vs Q3 2025
29positions
73.8%in top 10
8 new
11 added
7 reduced
12 sold out
vs Q3 2025
Options: 0 call positions (— notional), 1 put positions ($182.9m notional) – listed below, not included above.
Holdings, Q4 2025
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| NUVALENT INC COM | $530.1m14.19% | Unchanged |
| REVOLUTION MEDICINES INC RVMD | $529.2m14.17% | Added +421.1k |
| ARCELLX INC ACLX | $373.2m9.99% | Added +1.1m |
| GENMAB A/S GMAB | $216.8m5.81% | Added +3.2m |
| TARSUS PHARMACEUTICALS INC TARS | $209.8m5.62% | Reduced -103.5k |
| ABIVAX SA ABVX | $191.2m5.12% | Reduced -146.7k |
| OLEMA PHARMACEUTICALS INC OLMA | $188.6m5.05% | Added +750.0k |
| VAXCYTE INC PCVX | $187.7m5.03% | Added +283.3k |
| CIDARA THERAPEUTICS INC CDTX | $167.8m4.49% | Reduced -201.6k |
| EDGEWISE THERAPEUTICS INC EWTX | $162.3m4.35% | Added +371.1k |
| SCHOLAR ROCK HLDG CORP SRRK | $134.9m3.61% | Added +1.1m |
| UROGEN PHARMA LTD URGN | $104.8m2.81% | Added +257.6k |
| CRINETICS PHARMACEUTICALS IN CRNX | $102.9m2.76% | Reduced -340.0k |
| APOGEE THERAPEUTICS INC COM | $84.8m2.27% | Reduced -398.5k |
| EYEPOINT PHARMACEUTICALS INC EYPT | $67.4m1.81% | Added +1.7m |
| ERASCA INC ERAS | $52.7m1.41% | Added +599.1k |
| BRIDGEBIO PHARMA INC BBIO | $52.3m1.40% | Unchanged |
| ORUKA THERAPEUTICS INC ORKA | $51.8m1.39% | New |
| SPYRE THERAPEUTICS INC SYRE | $48.1m1.29% | Unchanged |
| LEXEO THERAPEUTICS INC LXEO | $47.3m1.27% | New |
| VIRIDIAN THERAPEUTICS INC VRDN | $44.9m1.20% | Reduced -1.2m |
| OCULAR THERAPEUTIX INC OCUL | $35.6m0.95% | Reduced -562.0k |
| TERNS PHARMACEUTICALS INC COM | $32.7m0.88% | New |
| BRIDGEBIO ONCOLOGY THERAPEUT BBOT | $28.3m0.76% | Added +395.6k |
| VOR BIOPHARMA INC VOR | $22.9m0.61% | New |
| ASSEMBLY BIOSCIENCES INC ASMB | $22.6m0.61% | New |
| ORIC PHARMACEUTICALS INC ORIC | $19.6m0.53% | New |
| INVENTIVA SA IVA | $18.6m0.50% | New |
| KALARIS THERAPEUTICS INC KLRS | $5.9m0.16% | New |
Sold out since Q3 2025
| Security | Value then |
|---|---|
| MERUS N V MRUS | $411.8m4.4m shares |
| AGIOS PHARMACEUTICALS INC AGIO | $107.3m2.7m shares |
| JANUX THERAPEUTICS INC JANX | $71.4m2.9m shares |
| ALKERMES PLC ALKS | $51.6m1.7m shares |
| LENZ THERAPEUTICS INC LENZ | $50.0m1.1m shares |
| PHARVARIS N V PHVS | $45.8m1.8m shares |
| COGENT BIOSCIENCES INC COGT | $45.3m3.2m shares |
| TANGO THERAPEUTICS INC TNGX | $25.9m3.1m shares |
| AMYLYX PHARMACEUTICALS INC AMLX | $25.8m1.9m shares |
| DYNE THERAPEUTICS INC DYN | $24.0m1.9m shares |
| DISC MEDICINE INC IRON | $16.4m247.7k shares |
| STRUCTURE THERAPEUTICS INC GPCR | $10.4m372.9k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| SPDR SER TR XBI · Put | $182.9m1.5m shares | Added |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 | 10.0%≈ $92.9m |
| EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 | 9.5%≈ $415.1m |
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 | 9.2%≈ $64.7m |
| ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 | 7.8%≈ $42.7m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 6.1%≈ $123.5m |
| TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 | 5.8%≈ $110.9m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 | 5.3%≈ $19.4m |
| MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 | 5.2%≈ $137.6m |
| SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 | 5.1%≈ $395.7m |
| JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 | 5.1%≈ $69.0m |